Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

v3.8.0.1
Segment reporting (Tables)
3 Months Ended
Oct. 31, 2017
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block] The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2017   Clinical
Labs
    Life
Sciences
    Therapeutics     Other     Consolidated  
Revenues:                                        
Clinical laboratory services   $ 20,334                       $ 20,334  
Product revenues         $ 7,081                   7,081  
Royalty and license fee income           261                   261  
      20,334       7,342                   27,676  
Operating costs and expenses:                                        
Cost of clinical laboratory services     12,042                         12,042  
Cost of product revenues           3,389                   3,389  
Research and development           523     $ 224             747  
Selling, general and administrative     6,095       2,614           $ 2,182       10,891  
Provision for uncollectible accounts receivable     800       14                   814  
Legal fee expense     13       3             415       431  
Total operating costs and expenses     18,950       6,543       224       2,597       28,314  
                                         
Operating income (loss)     1,384       799       (224 )     (2,597 )     (638 )
                                         
Other income (expense):                                        
Interest     (25 )     12             170       157  
Other     14       7             15       36  
Foreign exchange loss           (195 )                 (195 )
Income (loss) before income taxes   $ 1,373     $ 623     $ (224 )   $ (2,412 )   $ (640 )
                                         
Depreciation and amortization included above   $ 404     $ 326     $     $ 19     $ 749  
                                         
Share-based compensation included in above:                                        
Selling, general and administrative     32     $ 23           $ 150       205  
Total   $ 32     $ 23     $     $ 150     $ 205  
                                         
Capital expenditures   $ 418     $ 43     $     $     $ 461  
Three months ended October 31, 2016   Clinical
Labs
    Life
Sciences
    Therapeutics     Other     Consolidated  
Revenues:                                        
Clinical laboratory services   $ 18,558                       $ 18,558  
Product revenues         $ 7,426                   7,426  
Royalty and license fee income           300                   300  
      18,558       7,726                   26,284  
Operating costs, expenses and legal settlements, net:                                        
Cost of clinical laboratory services     10,896                         10,896  
Cost of product revenues           3,309                   3,309  
Research and development           627     $ 195             822  
Selling, general and administrative     5,952       2,946           $ 2,596       11,494  
Provision for uncollectible accounts receivable     666       3                   669  
Legal fee expense     52       12             308       372  
Total operating costs, expenses and legal settlements, net     17,566       6,897       195       2,904       27,562  
                                         
Operating income (loss)     992       829       (195 )     (2,904 )     (1,278 )
                                         
Other income (expense):                                        
Interest     (29 )     10             65       46  
Other     102                   17       119  
Foreign exchange loss           (361 )                 (361 )
Income (loss) before income taxes   $ 1,065     $ 478     $ (195 )   $ (2,822 )   $ (1,474 )
                                         
Depreciation and amortization included above   $ 401     $ 508     $     $ 18     $ 927  
                                         
Share-based compensation included in above:                                        
Selling, general and administrative     17     $ 11           $ 121       149  
Total   $ 19     $ 11     $     $ 121     $ 151  
                                         
Capital expenditures   $ 412     $ 102     $     $     $ 514